Lexeo CEO Lands $1.9 Million in RSU Grants—A Bold Bet on Gene‑Therapy Success Despite Stock Slide
Lexeo Therapeutics’ CEO buys 161,665 shares and 646,665 options – a strong leadership signal that hinges on upcoming clinical milestones and potential partnerships.
4 minutes to read